These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15475939)

  • 21. Clinical endpoints for drug development in prostate cancer.
    Ramiah V; George DJ; Armstrong AJ
    Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A contribution on lymphosarcoma of the prostate].
    Berger HJ
    Z Urol Nephrol; 1966 Jul; 59(7):489-91. PubMed ID: 6014790
    [No Abstract]   [Full Text] [Related]  

  • 23. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging drugs for prostate cancer.
    Siddiqui K; Klotz LH
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):455-70. PubMed ID: 19650748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The case for early chemotherapy for the treatment of metastatic disease.
    Lucas A; Petrylak DP
    J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer.
    Howard EW; Ling MT; Chua CW; Cheung HW; Wang X; Wong YC
    Clin Cancer Res; 2007 Mar; 13(6):1847-56. PubMed ID: 17363541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding bone metastases: the key to the effective treatment of prostate cancer.
    Fidler IJ
    Clin Adv Hematol Oncol; 2003 May; 1(5):278-9. PubMed ID: 16224421
    [No Abstract]   [Full Text] [Related]  

  • 28. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
    Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
    Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caring for a patient with metastatic prostate cancer.
    Held-Warmkessel J
    Nursing; 2008 Jun; 38(6):52-6. PubMed ID: 18497662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy for older patients with prostate cancer.
    Anderson J; Van Poppel H; Bellmunt J; Miller K; Droz JP; Fitzpatrick JM
    BJU Int; 2007 Feb; 99(2):269-73. PubMed ID: 16981902
    [No Abstract]   [Full Text] [Related]  

  • 31. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain metastases in hormone refractory prostate cancer: a changing natural history?
    Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K
    Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072
    [No Abstract]   [Full Text] [Related]  

  • 33. Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
    Martinez V; Mir O; Dômont J; Bouscary D; Goldwasser F
    Anticancer Drugs; 2007 Feb; 18(2):233-5. PubMed ID: 17159610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
    Ghosn M; Kattan J; Younes F
    Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
    [No Abstract]   [Full Text] [Related]  

  • 35. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
    Roehrborn CG; Lotan Y; Tubaro A; de Nunzio C
    Eur Urol; 2006 Feb; 49(2):396-400. PubMed ID: 16455190
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
    Huang CY; Beer TM; Higano CS; True LD; Vessella R; Lange PH; Garzotto M; Nelson PS
    Clin Cancer Res; 2007 Oct; 13(19):5825-33. PubMed ID: 17908975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of prostatic cancer (Drug Administration, Sweden)].
    Lakartidningen; 1993 May; 90(18):1766, 1769-73. PubMed ID: 8492635
    [No Abstract]   [Full Text] [Related]  

  • 38. [Does chemotherapy have a role in the treatment of prostatic cancer?].
    Verbaeys A
    Acta Urol Belg; 1991; 59(4):53-4. PubMed ID: 1819203
    [No Abstract]   [Full Text] [Related]  

  • 39. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer: chemoprevention update 2005.
    Fleshner N; Al Azab R
    Can J Urol; 2005 Jun; 12 Suppl 2():2-4. PubMed ID: 16018824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.